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Cognitive Function, Progression of Age-related Behavioral Changes,
Biomarkers, and Survival in Dogs More Than 8 Years Old
T. Sch€utt, N. Toft, and M. Berendt
Background: Canine cognitive dysfunction (CCD) is an age-dependent neurodegenerative condition dominated by changes
in behavioral patterns. Cohort studies investigating cognitive status in dogs are lacking.
Objectives: To investigate cognitive function, progression of age-related behavioral changes, survival, and possible
biomarkers of CCD in aged dogs.
Animals: Fifty-one dogs >8 years old; 21 with no cognitive deﬁcits, 17 with mild cognitive impairments (MCI) and 13
with CCD.
Methods: Longitudinal study. Recruitment period of 12 months and an observational period of 24 months including a
baseline and 3 planned subsequent assessments. Cognitive status was determined using validated questionnaires. Plasma Ab-
peptides were quantiﬁed using commercial ELISA assays and cytokines by a validated immunoassay.
Results: Signs characterizing dogs with CCD were aimless wandering, staring into space, avoid getting patted, diﬃculty
ﬁnding dropped food and anxiety. Thirty-three percent of dogs with a normal cognitive status progressed to MCI and 22%
classiﬁed as MCI progressed to CCD during the study period. For 6 dogs diagnosed with CCD, signs of cognitive dysfunc-
tion increased with time. A diagnosis of CCD did not aﬀect survival. The level of plasma Ab42 was signiﬁcantly increased
(P < .05) in the CCD group (92.8  24.0 pg/mL) compared to the MCI (77.0  12.3 pg/mL) and normal group
(74.9  10.0 pg/mL), but no signiﬁcant diﬀerences in concentrations of systemic inﬂammatory markers were detected.
Conclusions: Canine cognitive dysfunction is a progressive disorder with an individual variability in the rate of cognitive
decline and clinical signs. Plasma Ab42 seems to be an interesting plasma biomarker of CCD.
Key words: Amyloid-beta; Canine; Dementia; Geriatric; Longitudinal.
Senior dogs (those aged > 8 years) spontaneouslycan develop neurodegenerative cerebral changes and
associated impairment of cognitive functions. A speciﬁc
clinical syndrome characterized by cognitive changes
which are not normal for age and cannot be explained
by other medical conditions occurs in dogs more than
8 years of age1–3 and shares multiple similarities to
human dementia of the Alzheimer’s type.4–8 The syn-
drome is referred to as canine cognitive dysfunction
(CCD),2,9 cognitive dysfunction syndrome,1 and canine
counterpart of senile dementia of the Alzheimer’s
type.10 The term CCD shall be used in this article.
The prevalence of CCD ranges from 14 to 35% in
companion dogs more than 8 years of age, and the risk
of developing CCD increases exponentially with increas-
ing age.11–14 Changes in behavior and daily routines
are considered the most important clinical markers of
cognitive dysfunction in aged dogs. Therefore, the diag-
nosis of CCD is primarily driven by owner-based ques-
tionnaires and clinical rating scales addressing
behavioral alterations within the categories disorienta-
tion, social interaction, sleep-wake cycle disturbances,
house-soiling, and changes in activity.1,3,9,15,16 Further-
more, signs of fear and anxiety that have not been pre-
sent at a younger age are common in dogs with
CCD.1,2 Although developed from diﬀerent designs and
strategies, the dementia score from 3 of the existing
CCD screening questionnaires correlated well.10 The
result obtained from CCD questionnaires must, how-
ever, always be supported by a thorough clinical evalua-
tion in order to exclude systemic or primary behavioral
conditions that could possibly be causing the signs dis-
played by the aﬀected dog.1
The natural history of cognitive dysfunction in senior
dogs is sparsely documented.2,17 It is therefore desirable
to gain more information regarding the clinical pheno-
type, progression, and prognosis of CCD. For this pur-
pose, epidemiological longitudinal studies are needed.
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Another area of interest is to search for potential
biomarkers, which in the future might help clinicians to
identify dogs suﬀering from CCD and prompt early
supportive initiatives.
The aim of the present study was to provide longi-
tudinal information of cognitive function, progression
of age-related behavioral changes and survival in a
cohort of dogs more than 8 years old with and with-
out signs of cognitive dysfunction at study inclusion.
As easily accessible biomarkers for CCD are needed
in veterinary medicine, we also investigated if systemic
levels of Ab-peptides, cytokines, or inﬂammatory
markers were signiﬁcantly higher in dogs with CCD
compared to dogs with no or mild cognitive impair-
ments (MCI).
Materials and Methods
Study Design and Procedure
The study was designed as a prospective longitudinal cohort
study and was carried out at the Department of Veterinary
Clinical and Animal Sciences, University of Copenhagen from
February 2012 to April 2015. Client-owned dogs were recruited
consecutively through the community practice and neurology
referral clinic at the University Hospital for Companion ani-
mals.
The animals were treated according to the EU directive on han-
dling and protection of animals used for scientiﬁc purposes (2010/
63/EU) and the study was approved by the Ethical Committee of
the Department of Veterinary Clinical and Animal Science,
University of Copenhagen, Denmark. Informed and written con-
sent was obtained from all owners.
The inclusion criteria was that dogs should be more than
8 years old and exclusion criteria were brain diseases other than
CCD or concurrent medical problems that could possibly mimic
signs of cognitive impairment. The inclusion period was open from
February 2012 to March 2013 and the study period ended in May
2015.
The study design implicated a baseline assessment at inclusion
(E0), and 3 planned subsequent evaluations which served to moni-
tor cognitive status over time: Six months after inclusion (E1),
12 months after inclusion (E2), and 24 months after inclusion
(E3). All investigations were performed by the principal investiga-
tor (TS) to secure a structured and consistent evaluation of all
dogs.
The baseline assessment E0 served to recruit dogs and further-
more to categorize the study population into 3 groups; a cogni-
tively normal non-CCD group, a group with MCI, and a
cognitively impaired CCD group. All dogs had a medical and cog-
nitive evaluation including a clinical and neurological examination
and assessment of body condition score. The auditory and visual
system was evaluated as is standard in a full neurological examina-
tion. Hearing was tested by evaluating if the animal responded to
sudden and unexpected sounds. Vision was evaluated by observing
how the dog navigated in an unfamiliar environment and by test-
ing the menace response which includes evaluation of all visual
pathways. Additionally, the owner was instructed to report any
changes of behavior in the home environment which could indicate
a hearing or vision problem. The clinical evaluation also included
collection of blood samples for complete blood count, serum bio-
chemistry (inclusive of C-reactive protein and ﬁbrinogen), thyroid
proﬁle and quantiﬁcation of plasma Ab-peptides and circulating
cytokines. Further diagnostic work-up such as urinalysis, abdomi-
nal sonography, echocardiography, computed tomography (CT),
magnetic resonance imaging (MRI), or cerebrospinal ﬂuid analysis
(CSF) were performed as indicated at the discretion of the princi-
pal investigator. Cognitive evaluation was based on face-to face
interviews with the owners using the Canine Cognitive Rating
Scale (CCDR)9 (Table S1) and a supplementary CCD screening
questionnaire10 (Table S2). To address signs of fear and anxiety, 2
additional standardized questions were given to the owners. An
interview would last for a minimum of 30 minutes. Answers were
recorded for each dog in a separate ﬁle. The owners were encour-
aged to record their dog’s behavior on video and the video obser-
vations were included in the assessment of cognitive status when
available. Dogs were distributed into the non-CCD group, the
MCI group and the CCD group based on the scoring results from
the CCDR. According to the CCDR, a total score below 39 classi-
ﬁes a dog as having a normal cognitive status (non-CCD), a score
of 40–49 classiﬁes a dog as being at risk of developing CCD
(MCI), and a total score above 50 classiﬁes a dog as having CCD.
The owners were asked to consent to donate the dog for post-
mortem examination if the dog was euthanized by the principal
investigator during the study period.
Evaluations at 6 months and 24 months (E1 and E3) were con-
ducted as structured telephone interviews using the CCDR ques-
tionnaire9 and a supplementary CCD screening questionnaire.10
Evaluation at 12 months (E2) was performed as a clinical con-
trol visit and included the same investigations as performed at E0
except for quantiﬁcation of thyroid hormones, plasma Ab-pep-
tides and circulating cytokines. For dogs that were euthanized or
died spontaneously during the study period, the last investigator-
client contact was at time of death or at the ﬁrst coming
prescheduled contact.
Blood Sampling and Analysis
Blood samples were collected from the cephalic or jugular vein.
The hematologic and biochemical proﬁles (including C-reactive
protein, ﬁbrinogen, and thyroid hormones) were analyzed at the
Central Laboratory, Department of Veterinary Clinical and Ani-
mal Sciences, University of Copenhagen.
Blood samples for Ab and cytokine quantiﬁcation were col-
lected into vials containing EDTA, centrifuged (2,500 9 g,
15 minutes, 4°C), and plasma was immediately separated, snapfro-
zen on dry ice and stored at 80°C until batch analysis. Ab40 and
Ab42 was measured using commercially available ELISA sandwich
kits; Human bAmyloid(1–40) II and Human/Rat bAmyloid(42)
High-Sensitive.a The applied capture antibodies for the N-terminal
portion of human Ab40 and Ab42 are monoclonal anti-Ab1–16
(BAN50) and monoclonal Ab11–28 (BNT77), the C-terminal detec-
tion antibodies are HRP-conjugated anti-Ab1–40 (BA27) and anti-
Ab35–43 (BC05), respectively. All samples were initially diluted 1:1
in urea (8 M) in order to monomerize the Ab ﬁbrils and reveal
more epitopes to the detection antibody. Addition of urea to the
samples did not have any inﬂuence on the performance of the
ELISA kits from Wako.
N-terminal pyroglutamate-modiﬁed Ab was quantiﬁed using the
speciﬁc ELISA kit; Amyloid-b N3pE-42.b Capture antibody for
this assay is antihuman Ab(38–42) and the detection antibody is
HRP-conjugated anti-Ab N3pE (8E1). All samples were run in
duplicates and optical density (OD) values were measured at
450 nm using an ELISA plate reader.c
Plasma concentration of IL-2, IL-6, IL-8, and TNFa were
simultaneously measured with a commercially available canine-
speciﬁc multiplex immunoassay which employs an electrochemi-
luminescence detection technology.d The provided protocol for
custom assay was used with no major modiﬁcations. The low-
est detectable limit speciﬁed in the data sheet for IL-2, IL-6,
IL-8, and TNFa were 7.6, 2.4, 1.3, and 0.17 pg/mL,
respectively.
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Statistical Analysis
Descriptive analyses of the results obtained from the question-
naires and the additional questions regarding anxiety were carried
out stratiﬁed by cognitive status. One-way analysis of variance
(ANOVA) with post-tests (Tukey’s multiple comparison test) was
used for comparisons of parametric data from the 3 groups and
Kruskal-Wallis test with post-tests (Dunn’s multiple comparison
test) was used for ordinal variables. Because of low sample sizes
Fischer’s exact test was applied for analysis of contingency tables
containing 2 or 3 categorical variables. Correlations were assessed
graphically as well as by Pearson’s or Spearman Rank correlation
coeﬃcient where appropriate.
Survival curves, median survival time, and 95% conﬁdence
intervals were obtained by the Kaplan-Meier method and diﬀer-
ences in survival were tested by the log-rank test. Survival time
was counted from the day of birth to the day of death or right
censored at end of the study. Outcome registration ended ﬁrst of
May 2015, outcome was deﬁned as euthanasia primarily because
of behavioral changes as a consequence of CCD or euthanasia/
death because of other reasons.
Statistical signiﬁcance was deﬁned as P < .05. All statistical
analyses were conducted using commercial statistical
software.e
Results
Descriptive Data
A total of 57 privately owned dogs, 32 females and
25 males of various breeds, and ranging from 8 to
15 years (108–197 months) were enrolled in the study
during the inclusion period. A total of 6 dogs were
excluded, 3 dogs because of systemic disease, and 3
dogs because of inadequate owner interviews and
thereby insuﬃcient data, leaving a study population of
51 dogs. All dogs had a normal clinical and neuro-
logic examination. No deﬁcits of vision or hearing
that could account for the cognitive changes were
detected. Based on the scoring results from the
CCDR, 21 dogs were categorized in the non-CCD
group, 17 dogs in the MCI group, and 13 dogs in the
CCD group at E0.
The non-CCD group represented 14 diﬀerent breeds
and 4 mixed breeds with an age range of 106–
197 months. The MCI group represented 10 diﬀerent
breeds and 4 mixed breeds with an age range of 108–
192 months and the CCD group represented 7 diﬀerent
breeds and 4 mixed breeds with an age range of 127–
192 months.
There were no signiﬁcant diﬀerences with respect to
sex distribution, weight, and body condition score
between the cognitive groups at inclusion (Table 1). A
signiﬁcantly higher age was found for the dogs in the
CCD group compared to dogs in the non-CCD and
MCI groups (P = .04).
Fifteen dogs (10 dogs with CCD, 2 dogs with MCI
and 3 dogs with no signs of CCD) had a postmortem
examination of the brain using the trimming protocol
for evaluation of large-sized brains.18 Aside from corti-
cal thinning and ventricular enlargement which were
present in a number of CCD brains, no macroscopic
lesions were detected.
Clinical Phenotype of CCD
Table 2 shows the distribution of impaired behavioral
items for the 3 groups. The most frequent signs displayed
by dogs in the CCD group were “pacing/wandering with
no direction or aim” and “staring blankly at the walls or
ﬂoor” as 91.7% of dogs displayed this behavior once a
week or more frequently. “Avoiding being patted” and
“diﬃculty ﬁnding dropped food” was observed in 75% of
dogs in the CCD dogs. Supplementary questions revealed
that separation anxiety or irrational fear to well-known
objects/situations was observed in 33 and 58.3% of dogs
in the CCD group, respectively.
The below signs were signiﬁcantly more prevalent for
dogs in the CCD group than for dogs in the MCI
group: “avoids contact or being patted by the owner”
(P < .001), “much less active compared to 6 months
ago” (P < .05), “diﬃculty ﬁnding dropped food”
(P < .05), and “walks into doors or walls” (P < .05).
The proportion of dogs with aﬀected behavioral items
in the CCD group was signiﬁcantly higher than for the
proportion of dogs with aﬀected items in the non-CCD
group for all behavioral items except for “separation
anxiety” (P = .16), “irrational fear to well-known object
or situations” (P = .052), and “fails to recognize family
members” (P = .36).
Changes in Cognitive Status over Time
When analyzing changes in the CCDR score over
time for the individual dogs, we found that in the non-
CCD group 7 dogs (33%) progressed to the MCI group
from baseline assessment to death or end of study. Two
of these dogs progressed further from MCI to CCD.
For the MCI group, 4 dogs (22%) progressed into a
status of CCD from baseline assessment to death or
end of study. No dogs evaluated as CCD during the
study changed to a non-CCD or MCI status during the
study. Four dogs with CCD at E0 and the 2 dogs which
progressed from non-CCD to CCD displayed an
Table 1. Association between sex, weight, body
condition score, age, and cognitive status.
Non-CCD
(n = 21)
MCI
(n = 17)
CCD
(n = 13) P-value
Sex
Female 12 11 5 .25a
Male 9 6 8
Weight (kg)
Mean  SD 18.9  9.2 19.6  9.0 13.9  8.7 .20b
Body condition score (1–9)
Median 6 4 7 .11c
Lower quantile 5 4 4.5
Upper quantile 7 6 8
Age (months)
Mean  SD 148  22 149  22 167  19 .039b
CCD, canine cognitive dysfunction; MCI, mild cognitive impair-
ment. Categorization in cognitive groups is based on the total
canine cognitive ratings scale score.
P-values is calculated by: aFischer’s exact test, bANOVA, cKrus-
kal-Wallis test.
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increasing CCDR score with time. In 8 dogs (61.5%) in
the CCD group had died or were euthanized within
four months after the date of inclusion therefore no fol-
low-up evaluation was possible. The CCDR score and
time of death for the individual dogs from inclusion to
end of study period is illustrated in Fig 1.
Survival Analysis
At the last contact (C3), 41 dogs (82.4%) were dead
and 8 dogs (15.7%) were still alive. Two dogs (3.9%)
were lost for follow-up between E0 and E1. For the
survival analysis, the dogs were divided into 2 groups,
Table 2. Frequency distribution of number of dogs (and percentages) with aﬀected behavioral items in the
non-CCD, MCI, and CCD group.
Category Items
Non-CCD
(n = 21)
n (%)
MCI
(n = 16)
n (%)
CCD
(n = 12)
n (%) P-value$
Spatial orientation
Disorientation
Awareness
Gets stuck behind objects
and is unable to get
around (happens once a
week or more frequently)
1 (4.8) 7 (43.8) 6 (50) 1.0
Walks into doors or walls
(happens once a week or
more frequently)
1 (4.8) 1 (6.3) 6 (50) *
Stares blankly at walls or
ﬂoor (happens once a
week or more frequently)
4 (19) 9 (56.3) 11 (91.7) .09
Disoriented at home 0 2 (12.5) 4 (33) .43
Memory Fails to recognize familiar
people or pets (happens
once a week or more
frequently)
0 0 1 (8.3) .43
Indoor urination/
defecation in areas
previously kept clean
happens much more
compared to 6 months
ago
0 1 (6.3) 5 (41.7) .057
Activity—apathy Avoids contact or being
patted by the owner
(happens once a week or
more frequently)
3 (14.3) 1 (6.3) 9 (75) ***
Much less active compared
to 6 months ago
1 (4.8) 1 (6.3) 6 (50) *
Impaired olfaction Diﬃculty ﬁnding dropped
food in more than 31%
of times
0 4 (25) 9 (75) *
Locomotion Paces up and down or
wanders with no
direction/purpose
(happens more than once
a week)
2 (9.5) 13 (81.3) 11 (91.7) .61
Anxiety Separation anxiety arisen
after 8 years of age
2 (9.5) 0 4 (33.3) ***
Irrational fear to well-
known objects/situations
5 (23.8) 2 (12.5) 7 (58.3) *
Learning and memory Decreased ability/slow to
learn new tasks
4 (19) 6 (37.5) 9 (75) **
Decreased ability to
perform known tasks
0 6 (37.5) 7 (58.3) .45
Sleep-wake cycle Sleeps at day and restless
at night
0 5 (33) 5 (41.7) .70
CCD, canine cognitive dysfunction; MCI, mild cognitive impairment. Categorization in cognitive groups is based on the total canine
cognitive ratings scale score.
Data were derived from the inclusion visit (C0) as we wished to include answers from the ﬁrst time the owner were given the question-
naires. Note that for 2 dogs (1 dog in the MCI group and 1 dog in the CCD group), speciﬁc data from the canine cognitive dysfunction
rating scale are missing at inclusion, therefore these dogs are excluded in this analysis.
$P-values corresponding to statistical signiﬁcant diﬀerences between the MCI and the CCD group.
*P < .05, **P < .01, ***P < .001.
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a control group which consisted of 33 dogs that
had non-CCD or MCI at baseline evaluation and no
progression of cognitive status from non-CCD/MCI
to CCD from baseline to death/end of study. The sur-
vival of this group was compared to the CCD group
which consisted of 19 dogs that was diagnosed
with CCD at baseline evaluation or had progressed
to develop CCD during the study. Median survival
time was 4,844 days for the control group and
5,367 days for CCD dogs (log-rank test P-value of
.62). The mean follow-up time from inclusion to death
for this study was 406 days (range from 0 to
1,113 days).
Plasma Biomarkers
There were no signiﬁcant diﬀerences in concentra-
tions of biochemical and hematological parameters
between the non-CCD, MCI, and CCD groups (data
not shown). The mean Ab concentrations and Ab42/
Ab40 ratio for each group are shown in Table 3. Con-
centration of plasma AbpN3-42 was nonquantiﬁable as
all samples were below lower limit of detection
(7.75 pg/mL). Levels of Ab40 correlated well with Ab42
level across the study groups (r = 0.59, P < .0001).
Plasma concentration of both Ab40 and Ab42 varied
considerably between dogs in all 3 groups, as denoted
Fig 1. The canine cognitive dysfunction rating scale score and time of death for the individual dogs from inclusion to end of study period.
The red lines indicate the cut-oﬀ values between cognitive groups. Note that for dogs which died between 2 preplanned assessments, time
of death will appear in the ﬁgure at the next preplanned evaluation. At 24-month evaluation, 5 dogs had died between the 12 months and
the 24 months evaluation and 8 dogs were still alive, thus evaluation was accomplished for 13 dogs in total.
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by the high standard deviations (SD). The CCD group
revealed signiﬁcantly higher levels of plasma Ab42 levels
(P < .05) than the MCI and the non-CCD group
(Fig 2).
Nevertheless, individual values of Ab42 measurements
showed considerable overlap between the 3 groups.
Within the CCD group, a wide dispersion of the Ab42
measurements was present resulting in an apparent dis-
tribution into 2 clusters. One cluster of 7 CCD dogs
had Ab42 levels above 95 pg/mL and for the other clus-
ter consisting of 6 dogs, the Ab42 levels were less than
80 pg/mL. No signiﬁcant diﬀerence in CCDR score was
evident between the 2 clusters of CCD dogs. An
increased plasma level of Ab40 (r = 0.39, P < .005) and
Ab42 (r = 0.31, P < .05) were positively correlated with
the CCDR score. Ab40 levels or the Ab42/Ab40 ratio
was not signiﬁcantly diﬀerent between groups.
Concentrations of CRP, ﬁbrinogen, and IL-8 were
quantiﬁed in all dogs. IL-2 and IL-6 could not be quan-
tiﬁed in plasma from 56 and 33% of the dogs, respec-
tively, as measurements were below the lower limit of
detection. Measurements of plasma TNFa could not be
quantiﬁed or were just above lower detection limit in all
dogs. Dogs with non-quantiﬁable concentrations of IL-
2 and IL-6, and all TNFa measurements were excluded
from the statistical analysis. There were no signiﬁcant
diﬀerences in concentrations of any of the systemic
cytokines, C-reactive protein, or ﬁbrinogen between
dogs with CCD and dogs with no or MCI (data not
shown).
Discussion
This study investigated cognitive function in a cohort
of senescent dogs in a prospective longitudinal study
design. The clinical phenotype associated with cognitive
dysfunction in older dogs has been compared to
humans suﬀering from Alzheimer’s disease (AD),4–8,19,20
and our study supported that striking similarities exists
when evaluating the clinical appearance of aﬀected
dogs. The study documented that some dogs will
develop signs of cognitive dysfunction with increasing
age, whereas others remain cognitively healthy. Clinical
signs of cognitive decline in dogs with CCD are
cumulative and will worsen over time. This is also the
case for humans developing (AD).21,22 Based on the
scoring results from the CCDR, the categories which
were most aﬀected in dogs with CCD were social inter-
action, activity, spatial orientation, and sleep-wake
cycle, consistent with other studies.2,11,13 With respect
to speciﬁc clinical signs, “aimless wandering,” “staring
blankly into space,” “avoiding being patted,” and “diﬃ-
culty with ﬁnding dropped food” were the most com-
mon signs displayed by dogs with CCD (Table 2).
Decreased recognition of familiar people was an uncom-
mon sign in CCD dogs in the present study. This is in
accordance with that has been reported in 2 previous
studies,2,16 but in contrast to another study which
reported that decreased recognition of familiar people
was present in 60% of dogs with severe behavioral
changes and thus a dominant sign of CCD.9 The dis-
crepancy between studies is most possibly explained by
variations in the age and disease severity displayed by
the animals included in the study populations. Further-
more, a factor which hampers comparisons between
studies is that diﬀerent questionnaires which do not
necessarily address the same behavioral categories have
been used to assess cognitive status.
Except for the CDS checklist,1 the CCDR is the only
CCD screening questionnaire which has also incorpo-
Table 3. Concentration of plasma Ab40 and Ab42 (pg/mL) and Ab42/40 ratios.
Group Ab40 (pg/mL) Ab42 (pg/mL) Ab42/Ab40
Non-CCD (n = 21) 276.1  63.0 74.9  10.0 0.28
MCI (n = 17) 314.8  89.4 77.0  12.3 0.26
CCD (n = 13) 369.3  100.9*non-CCD 92.8  24.0**non-CCD, MCI 0.26
CCD, canine cognitive dysfunction; MCI, mild cognitive impairment. Categorization in cognitive groups is based on the total canine
cognitive ratings scale score.
*P < .01 to the non-CCD group; **P < .01 to the non-CCD group, and P < .05 to the MCI group.
Fig 2. Plasma Ab40 and Ab42 measurements for individual dogs
stratiﬁed by cognitive status. MCI, mild cognitive impairment;
CCD, canine cognitive dysfunction.
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rated “diﬃculty ﬁnding dropped food” as an indicator
of decreased olfaction. This sign was prevalent in CCD
dogs in this study population. Decreased olfaction has
previously been associated with CCD9 and our results
support that this sign could be a possible clinical indica-
tor for CCD. Olfactory dysfunction and more speciﬁc
impaired odor identiﬁcation have also been reported for
patients with AD and is presently investigated as an
early marker of preclinical AD.23–25
Only few studies exploring CCD have investigated
anxiety and fear as signs of signiﬁcant interest.1,2 This
is quite surprising given that behavioral changes related
to fear, phobias and anxiety have previously been
reported to be prevalent signs by owners of senior
dogs.26 Such signs are presumably comparable to agita-
tion and anxiety which is well known in humans with
MCI and AD.27,28 Our research group has previously
shown that anxiety and fear are common in dogs with
CCD,2 which was why we also found it of importance
to investigate such signs in this study. We found that
separation anxiety and irrational fear to well-known
objects/situations were present in 33% and 58% of dogs
with CCD, respectively. This is even higher than the
one previously reported2, and emphasize both the
importance of including questions addressing anxiety in
future CCD screening questionnaires and the need to
treat dogs with such troubling problems.
We used the CCDR for assessment of cognitive sta-
tus as it is very useful for monitoring the progression
of cognitive dysfunction.9 A progression of the CCDR
score over time was documented to occur in dogs from
all groups (non-CCD, MCI, and CCD) and some dogs
progressed from having mild cognitive disturbances
(MCI) to displaying convincing signs of CCD. Our
results supports that a preclinical stage of CCD is pre-
sent in a subset of aged dogs. As previously reported,
some dogs with MCI will develop CCD, whereas others
will never progress.2 In humans, such a symptomatic
pre-dementia phase is recognized as MCI due to AD.29
Only a proportion of human patients identiﬁed with
mild cognitive deﬁcits experience successive worsening
of cognitive impairment, which eventually develops into
fulminant AD.29,30 For 2 dogs with a normal cognitive
status at baseline assessment, a signiﬁcant progression
of the CCDR score was reported at E1 and the CCDR
score was further increased at E2, now categorizing the
dogs as CCD. Both dogs were evaluated at E2, where
no other medical causes than CCD could explain the
rapid progression of cognitive impairment. This study
demonstrates how the rate of progression of cognitive
impairment can be variable between individuals and
compares to the progressive phases of dementia severity
reported for human AD.29,31
In this study, median survival time for dogs with
CCD was not signiﬁcantly diﬀerent from dogs which
experienced healthy aging. We have previously investi-
gated survival with CCD2 where CCD dogs had a
longer survival time than non-CCD dogs. We specu-
lated that this was possibly because of a close investiga-
tor-client contact which motivated the owners to keep
dogs with CCD despite their cognitive deterioration.
Because of the longitudinal design of this study, the
investigator-client contact was even more consistent and
in theory this might inﬂuence survival time for dogs
with CCD even more positively. However, it might sim-
ply be that dogs with CCD do not experience a reduced
life span because of the fact that the disease debut is
late in life and because the human-animal bond is
strong.
It is of great importance to search for diagnostic tests
which can support a clinical suspicion of CCD and
detect cases of MCI. We investigated selected biomark-
ers and found that plasma Ab42 was signiﬁcantly higher
in the groups of CCD dogs compared to the MCI and
non-CCD groups. There was more variation in the level
of Ab42 in the group of CCD dogs compared to the
MCI and non-CCD group. This might imply that some
CCD dogs have an increased level because of some
underlying causes or that there is simply more variation
in the CCD group. However, we do not have full expla-
nation for this variation and further investigations
including a larger study population is needed in order
to examine this ﬁnding in more detail. The present
study was a small-scale study and studies with more
statistic power including serial plasma and possibly
CSF measures would be beneﬁcial to investigate if Ab42
is truly a relevant blood biomarker for CCD. Our
results are supported by a previous study which
reported signiﬁcantly higher plasma Ab42 levels in cog-
nitive impaired companion dogs compared to age-
matched controls.16 However, they also reported that
dogs with severe cognitive impairments had lower Ab42
level than dogs with MCI, which was not the case in
this study. There are several restrictions when compar-
ing the results from the 2 studies. One striking diﬀer-
ence is the substantially higher levels of both Ab40 and
Ab42 and the lower variation in measurements recorded
in our study. This diﬀerence might be explained by Ab
peptides binding to carrier proteins in plasma thus
masking the epitopes and underestimating true Ab val-
ues.32 To minimize the risk of epitope masking, we pre-
treated the plasma samples with urea. Another factor
adding to discrepancy between ELISA measurements
from diﬀerent studies could be because of diversity of
the applied antibodies, exhibiting varying sensitivities
and sometimes poorly deﬁned speciﬁcities.33
A meta-analytic review concluded that it is not possible
to establish a clear relationship between plasma Ab pep-
tide levels and clinical measures of AD severity.33 Thus, a
model of diﬀerential longitudinal changes in plasma Ab42
levels in cognitively stable human subjects versus those
who go on to develop AD dementia has been proposed.33
Individuals that will develop AD have a higher baseline
Ab42 than cognitively stable individuals and the plasma
levels will increase gradually during the MCI phase. At
the conversion point fromMCI to AD plasma Ab42 levels
will diminish. Ab levels in cognitively stable individuals
will increase slightly with age.33
We speculate that the ﬁnding of higher plasma Ab42
levels in the CCD dogs compared to the cognitively
unimpaired dogs in this study reﬂects that dogs with
CCD are not as cognitively impaired as people with AD
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and thus may correspond to early AD or the MCI phase.
To gain a better understanding of plasma Ab across the
cognitive spectrum, longitudinal studies designed to
include multiple time points for Ab quantiﬁcations and
where the enrolled dogs have the same age at inclusion
would be beneﬁcial. Validation against other biomarkers
and histopathology would also be interesting.
The role of neuro-inﬂammation in disease progression
of AD has been extensively studied. Fibrils of Ab are
believed to induce microglia activation with subsequent
release of both pro- and anti-inﬂammatory mediators.34–
36 Complement factors, acute phase proteins, reactive
oxygen species and cytokines such as IL-6 and TNFa are
considered among the most prominent neurotoxic fac-
tors.35 Circulating cytokine concentrations in dogs with
CCD have not been examined previously. Several of the
cytokines investigated in this study could not be quanti-
ﬁed although internal controls (spike recovery) were
within acceptable limits and calibrations were valid.
Although our results do not show a signiﬁcant diﬀerence
in circulating cytokine concentrations in dogs with CCD,
a role for cytokines in the pathogenesis of CCD cannot
be excluded. Local changes in the cerebral cortex of cyto-
kine expression might possibly be more pronounced than
reﬂected in the systemic concentrations.
Conclusions
This study documented that CCD is a progressive
condition where the course of disease varies between
individuals and thus compares to the progression
through successive phases in human AD. Dogs with
CCD commonly display speciﬁc clinical signs such as
aimless wandering, staring blankly into space, avoiding
being patted, and diﬃculty with ﬁnding dropped food.
Furthermore, signs related to anxiety and unexplained
fear is also common and should be addressed in future
CCD screening questionnaires. Plasma Ab42 was found
to be highest in dogs from the CCD group and thus
may represent an interesting plasma biomarker which,
however, needs further investigation.
Footnotes
a Wako Pure Chemical Industries, Ltd., Japan. Cat. no. 298-64601
and 292-64501
b Immuno-Biological Laboratories Co., Ltd., Gunma, Japan. Cat.
no. JP27716
c Multiscan FC, Fisher Scientiﬁc UK Ltd., Leicestershire, England
d Canine Proinﬂammatory Panel 3 Assay, Meso Scale Discovery,
Rockville, MD
e GraphPad Prism 4.03 for Windows, GraphPad Software, La
Jolla, CA
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Table S1. Questions and scores included in the
Canine Cognitive Dysfunction Rating Scale developed
by Salvin and co-workers.9
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the questionnaire developed by Roﬁna and co-workers.10
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